LifeCare Pharmaceutical Trading PLC maintains more than 225 medicines and medical devices registered with the Ethiopian Food and Drug Authority (EFDA). Each one carries a five-year clock, a renewal window that opens 180 days before it closes, a change-control file that has to stay current, and a safety-reporting duty that runs for as long as the product sits on a shelf in Ethiopia.
Two hundred and twenty five of those, each with its own approval date scattered across the calendar, take a full-time regulatory function to keep current. Below is the rulebook that function answers to, which is also the rulebook you can hold any Ethiopian supplier against.
Every EFDA registration expires: the five-year clock and the 180-day window
Marketing authorization in Ethiopia rests on three instruments: Food and Medicine Administration Proclamation 1112/2019, Council of Ministers Regulation 531/2023, and Medicine Marketing Authorization Directive 963/2023. Article 20(6) of the proclamation and article 20 of the directive agree on the central point. Every registered medicine has its marketing authorization renewed every five years, and the product registration certificate is valid for five years, full stop.
Buyers rarely see how unforgiving the renewal timetable gets. EFDA’s Guideline for Renewal of Marketing Authorization (document EFDA/GDL/018) sets it out in three steps:
- The renewal application must be filed within 180 days before the due date, through eRIS and nowhere else.
- Miss that window and there is one further 180 days, on payment of a fee equivalent to a brand-new application.
- Miss the second window and the authorization is considered revoked. There is no route back to the old file. The product needs a complete new dossier, and until that clears it cannot legally be sold.
Products approved through the conditional approval route are tighter still, valid for one year. An emergency use authorization lasts only as long as the Ministry of Health keeps the emergency declaration standing.
So a missed renewal date lands on a hospital that budgeted for a line item and finds it unavailable, and on a manufacturer that loses market access it spent two years earning. That is the cost of treating registration as a one-off event.
Pillar one: building a dossier that survives evaluation
We submit registration applications through eRIS, EFDA’s Electronic Regulatory Information System, and each application names a focal technical person who owns the file. The dossier goes together with the manufacturer: quality, safety and efficacy data, a valid Good Manufacturing Practice certificate and manufacturing licence, and a Certificate of Pharmaceutical Product that must still be in date at the moment of submission.
Two details decide whether that file moves or stalls. EFDA evaluates applications in a queue rather than by whoever pushes hardest, and when it raises a deficiency, the applicant has 15 days to supplement the file. That deadline is why a registration function has to be staffed rather than handed to whoever is free that week. A query on a technical point in the stability data will not wait for an email chain across three time zones to resolve itself.
Directive 963/2023 also gives EFDA authority to process certain applications on an expedited basis, which matters for products filling a real gap in national supply. We walk through the full submission sequence, from competence certificate to port clearance, in our guide on how to import medicine into Ethiopia.
Devices and diagnostics follow their own route
A portfolio spanning therapeutics, surgical disposables, diagnostic materials and capital equipment is not one workflow repeated 225 times. EFDA classifies medical devices by risk, running Class I to Class IV for non-IVD devices and Class A to Class D for in vitro diagnostics, with the evidence burden rising at each step. Higher-class devices need documentation that a pharmaceutical dossier never touches, and that shows up as longer lead times on procurement. We cover the timing in our buyer’s guide to medical equipment imports.
Pillar two: the obligations that start after the certificate arrives
Three duties then run continuously for the life of every product, and they are where a company that holds registrations pulls away from one that obtained them years ago.
Variations: four reporting types, four different rules
A registered medicine does not stand still. Manufacturers change an excipient supplier, move a packaging site, revise an analytical method, update a leaflet. EFDA’s Guideline on Variation Applications to Registered Medicines sorts every one of those changes into four reporting types:
- Annual notification (AN). Minimal impact. Submitted within 12 months of implementing the change, with the supporting documentation held ready for inspection rather than filed up front.
- Immediate notification (IN). Implemented at the point of submission, and deemed accepted if EFDA raises no objection within 30 calendar days of acknowledging receipt.
- Minor variation (Vmin). Prior approval required before the change goes anywhere near a production batch.
- Major variation (Vmaj). Changes with potential major effects on safety, efficacy or quality. Prior acceptance required, with the full data package.
Notifications are not a formality. EFDA can reject an AN or an IN after the fact, and the holder then has to stop applying a change already running in production. Put a major variation in the wrong category and a compliant product quietly stops being one.
Pharmacovigilance: a named person, resident in Ethiopia
Under article 14 of Ethiopia’s Pharmacovigilance Directive 932/2015, every marketing authorization holder has to operate a pharmacovigilance system, appoint a Qualified Person for Pharmacovigilance, maintain a risk management plan and report adverse events. EFDA’s National Pharmacovigilance Guideline then puts hard edges on all of it.
The QPPV has to be a full-time permanent employee rather than a consultant on retainer, resident in Ethiopia and reachable around the clock. They must be a healthcare professional with a bachelor’s degree at minimum and at least two years of pharmacovigilance experience, and EFDA has to be told within 14 days if the post falls vacant.
The reporting clocks are just as plain. A serious adverse event is notified within 24 hours and reported to the national pharmacovigilance centre within 48 hours. Non-serious events go in within 7 working days. On top of that sits the periodic safety update report, due every six months for a new product’s first two years, annually for the next three, then every three years. If no adverse events came in at all, the holder still files a null report saying so.
Why the local agent carries real liability
Overseas manufacturers sometimes treat the Ethiopian local agent as a mailbox. The regulations do not read that way. Both parties sign and stamp the agency agreement, it is lodged through eRIS, and EFDA’s renewal guideline spells out what the agent is signing up to.
The agreement must state that if fraud or an unacceptable adverse event occurs under normal use, all parties named in it, the local agent included, are responsible for collecting the product from the market and for substantiating the consequences. Both sides carry pharmacovigilance and post-marketing follow-up on safety, quality and efficacy, and the agreement itself has to contain a post-market risk management plan. The agent handling a renewal is expected to be a pharmacist working in the pharmaceutical field, and cannot import the products at all without a valid EFDA competence certificate and a trading licence. Where a manufacturer appoints several distributors, renewal correspondence still runs through one named agent.
So a recall obligation, a safety obligation and a professional qualification requirement all rest on the Ethiopian partner. That makes the choice of local agent a quality decision with commercial consequences attached, and it is worth reading next to our checklist on how to verify a medicine supplier in Ethiopia.
Ethiopia’s regulator is tightening, and the record shows it
In September 2025, WHO recognised Ethiopia as having reached Maturity Level 3 for its medicines and vaccines regulatory system, making EFDA the ninth national regulator in Africa to get there, alongside Egypt, Ghana, Nigeria, South Africa, Tanzania, Zimbabwe, Senegal and Rwanda (WHO, 30 September 2025). ML3 describes a stable, well-functioning and integrated system with demonstrated capacity to authorize products, run market surveillance and monitor safety events. WHO Regional Director for Africa Dr Mohamed Yakub Janabi framed the point plainly: a strong regulatory system means patients can trust that the medicines they take are safe, effective and of assured quality.
EFDA’s own sector development plan shows what that looks like in enforcement terms. Adverse drug event reports climbed from 706 in 2017/18 to 8,004 in 2022/23, still short of an 11,000-per-year target. Over the same stretch EFDA took regulatory measures on 34 medicines, recalled 33 of them, withdrew marketing authorizations and closed manufacturing facilities (EFDA, FHRSDIP 2023 to 2026). The same plan sets a target of cutting average medicine recall time to 15 days.
Fifteen days is the figure worth sitting with. A recall on that timetable works only if the holder can identify every batch, every consignee and every remaining unit at short notice, which comes from record-keeping done during registration and distribution. Nobody assembles that during the recall itself.
Ethiopia has also launched a National Strategy to Combat Substandard and Falsified Medical Products covering 2026 to 2030, and local production has passed 40% of medicine supply against a national target of meeting half of essential-medicine demand domestically (World Bank, 26 May 2026). Behind all of it sits WHO’s estimate that roughly 1 in 10 medical products in low and middle income countries is substandard or falsified. Regulatory tightening is the response to that number, and suppliers who cannot keep up with it will be squeezed out.
Check the register rather than the claim
Any supplier can say it is compliant. EFDA publishes a public registry so you do not have to take that on trust. Search registered products, listed manufacturers and licensed wholesalers at eris.efda.gov.et, with no account needed.
Evaluating an Ethiopian supplier, ours included, starts there. Look up the specific product you intend to buy rather than confirming the company exists. A competence certificate licenses a business to trade. Product registration is granted item by item, and each item on that register went through evaluation and is being kept there.
What 225 registrations mean in practice
For a hospital or wholesaler, the products you order are legally importable today and someone is watching the renewal dates, so an expiry does not reach you as a stockout your dispensary discovers on a Monday morning. For a manufacturer weighing up Ethiopia, the registration workload, the variation filings, the pharmacovigilance system and the recall liability all have somewhere to sit from the first shipment.
The count itself keeps moving as we register new lines and retire old ones. Every file on it was evaluated by a regulator now assessed at WHO Maturity Level 3, and every one of them has to be defended again in five years.
Frequently asked questions
How long is an EFDA product registration valid?
Five years. Under Proclamation 1112/2019 article 20(6) and Medicine Marketing Authorization Directive 963/2023 article 20, every registered medicine must have its marketing authorization renewed every five years, and the product registration certificate is valid for that period. Products approved under conditional approval are valid for one year, and emergency use authorizations last only while the Ministry of Health emergency declaration remains in force.
What happens if an EFDA registration renewal is filed late?
The renewal application should be filed within 180 days before the due date. If it is not, EFDA allows a further 180 days, but the applicant must pay a fee equivalent to a new application. If the renewal is still not filed after that second window, the authorization is considered revoked and the product has to go through a complete new dossier submission before it can be sold again.
How do I check whether a product is registered with EFDA?
Search EFDA’s public eRIS registry at eris.efda.gov.et, which lists registered products, manufacturers and licensed wholesalers and needs no login. Check the specific product rather than only the company. A trading licence or competence certificate covers the business, while product registration is granted item by item.
What is a variation application, and when is one required?
A variation is any post-registration change to a registered medicine, from a new excipient supplier to revised labelling. EFDA classifies them as annual notifications, immediate notifications, minor variations or major variations. Annual notifications are filed within 12 months of implementation, immediate notifications are accepted if no objection is raised within 30 calendar days, and both minor and major variations require EFDA approval before the change is implemented.
What responsibility does a local agent have for a foreign manufacturer’s product in Ethiopia?
More than most manufacturers expect. The agency agreement lodged with EFDA must state that all named parties, including the local agent, are responsible for collecting the product from the market if fraud or an unacceptable adverse event occurs, and that both sides handle pharmacovigilance and post-marketing follow-up. The agreement must include a post-market risk management plan, and the agent processing renewals is expected to be a pharmacist holding a valid EFDA competence certificate and trading licence.
Working with a partner who carries the compliance load
LifeCare builds and maintains EFDA registrations across pharmaceuticals, medical supplies and disposables and medical equipment for the Ethiopian market, alongside our own local manufacturing in Addis Ababa. If you manufacture abroad and need a local agent who will run the file rather than forward the post, see how we work with our partners. If you are buying, tell us what you need and when.
